ProQR Therapeutics NV (NASDAQ:PRQR) has been given a consensus rating of “Buy” by the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $28.00.
A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, January 11th. BidaskClub upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Finally, ValuEngine upgraded shares of ProQR Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 28th.
Shares of NASDAQ:PRQR opened at $8.47 on Tuesday. The company’s 50 day moving average price is $8.44 and its two-hundred day moving average price is $7.88. ProQR Therapeutics has a 12-month low of $5.49 and a 12-month high of $16.07. The firm has a market cap of $411.23 million, a PE ratio of -5.72 and a beta of 0.41. The company has a quick ratio of 7.01, a current ratio of 7.01 and a debt-to-equity ratio of 0.18.
Large investors have recently made changes to their positions in the business. Citigroup Inc. grew its position in shares of ProQR Therapeutics by 274.2% during the 4th quarter. Citigroup Inc. now owns 3,828 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 2,805 shares in the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $40,000. Jane Street Group LLC acquired a new stake in shares of ProQR Therapeutics during the 2nd quarter worth approximately $92,000. Northern Trust Corp boosted its position in shares of ProQR Therapeutics by 12.6% during the 2nd quarter. Northern Trust Corp now owns 38,742 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 4,345 shares in the last quarter. Finally, California Public Employees Retirement System acquired a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $494,000. Hedge funds and other institutional investors own 43.98% of the company’s stock.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Further Reading: Derivative
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.